The effects of phenoxodiol on the cell cycle of prostate cancer cell lines

详细信息    查看全文

• 作者：Simon Mahoney ; Frank Arfuso ; Michael Millward…
• 关键词：Phenoxodiol ; Cell cycle ; Prostate cancer ; Cytotoxicity
• 刊名：Cancer Cell International
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：1,108 KB
• 参考文献：1. Montero, A, Fossella, F, Hortobagyi, G, Valero, V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6: pp. 229-239 g/10.1016/S1470-2045(05)70094-2" target="_blank" title="It opens in new window">CrossRef
  2. Canfield, SE, Zhu, K, Williams, SA, McConkey, DJ (2006) Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5: pp. 2043-2050 g/10.1158/1535-7163.MCT-05-0437" target="_blank" title="It opens in new window">CrossRef
  3. Hanahan, D, Weinberg, RA (2000) The hallmarks of cancer. Cell 100: pp. 57-70 g/10.1016/S0092-8674(00)81683-9" target="_blank" title="It opens in new window">CrossRef
  4. Marieb E, Hoehn K: g class="a-plus-plus">Human Anatomy and Physiology.g> 9th edition. Sydney: Pearson; 2012.
  5. Cooper, S (2003) Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. FASEB J 17: pp. 333-340 g/10.1096/fj.02-0352rev" target="_blank" title="It opens in new window">CrossRef
  6. Pardee, AB (1974) A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 71: pp. 1286-1290 g/10.1073/pnas.71.4.1286" target="_blank" title="It opens in new window">CrossRef
  7. Michaud, LB, Valero, V, Hortobagyi, G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23: pp. 401-428 g/10.2165/00002018-200023050-00005" target="_blank" title="It opens in new window">CrossRef
  8. Gan, L, Wang, J, Xu, H, Yang, X (2011) Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 71: pp. 1158-1166 g/10.1002/pros.21331" target="_blank" title="It opens in new window">CrossRef
  9. Constantinou, AI, Husband, A (2002) Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 22: pp. 2581-2585
  10. Morre, DJ, McClain, N, Wu, LY, Kelly, G, Morre, DM (2009) Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Mol Biotechnol 42: pp. 100-109 g/10.1007/s12033-008-9132-x" target="_blank" title="It opens in new window">CrossRef
  11. Mahoney, S, Arfuso, F, Rogers, P, Hisheh, S, Brown, D, Millward, M, Dharmarajan, A (2012) Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci 37: pp. 73-84 g/10.1007/s12038-011-9170-6" target="_blank" title="It opens in new window">CrossRef
  12. Wasylishen, AR, Penn, LZ (2010) Myc: the beauty and the beast. Genes Cancer 1: pp. 532-541 g/10.1177/1947601910378024" target="_blank" title="It opens in new window">CrossRef
  13. Ladha, MH, Lee, KY, Upton, TM, Reed, MF, Ewen, ME (1998) Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol Cell Biol 18: pp. 6605-6615
  14. Koda, M, Sulkowska, M, Kanczuga-Koda, L, Tomaszewski, J, Kucharczuk, W, Lesniewicz, T, Cymek, S, Sulkowski, S (2007) The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer. Oncol Rep 18: pp. 113-119
  15. Roy, S, Kaur, M, Agarwal, C, Tecklenburg, M, Sclafani, RA, Agarwal, R (2007) p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 6: pp. 2696-2707 g/10.1158/1535-7163.MCT-07-0104" target="_blank" title="It opens in new window">CrossRef
  16. Hanahan, D, Weinberg, RA (2011) Hallmarks of cancer: the next generation. Cell 144: pp. 646-674 g/10.1016/j.cell.2011.02.013" target="_blank" title="It opens in new window">CrossRef
  17. Ahmad, I, Patel, R, Liu, Y, Singh, LB, Taketo, MM, Wu, XR, Leung, HY, Sansom, OJ (2011) Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2: pp. e124 g/10.1038/cddis.2011.7" target="_blank" title="It opens in new window">CrossRef
  18. Bott, SR, Arya, M, Kirby, RS, Williamson, M (2005) p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Dis 8: pp. 321-326 g/10.1038/sj.pcan.4500822" target="_blank" title="It opens in new window">CrossRef
  19. Xie, W, He, Y, Huo, D, Huang, Y, Wu,
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

Background Prostate cancer is associated with a poor survival rate. The ability of cancer cells to evade apoptosis and exhibit limitless replication potential allows for progression of cancer from a benign to a metastatic phenotype. The aim of this study was to investigate in vitro the effect of the isoflavone phenoxodiol on the expression of cell cycle genes. Methods Three prostate cancer cell lines-LNCaP, DU145, and PC3 were cultured in vitro, and then treated with phenoxodiol (10?μM and 30?μM) for 24 and 48?h. The expression of cell cycle genes p21WAF1, c-Myc, Cyclin-D1, and Ki-67 was investigated by Real Time PCR. Results Here we report that phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle, with the resultant arrest due to the upregulation of p21WAF1 in all the cell lines in response to treatment, indicating that activation of p21WAF1 and subsequent cell arrest was occurring via a p53 independent manner, with induction of cytotoxicity independent of caspase activation. We found that c-Myc and Cyclin-D1 expression was not consistently altered across all cell lines but Ki-67 signalling expression was decreased in line with the cell cycle arrest. Conclusions Phenoxodiol demonstrates an ability in prostate cancer cells to induce significant cytotoxicity in cells by interacting with p21WAF1 and inducing cell cycle arrest irrespective of p53 status or caspase pathway interactions. These data indicate that phenoxodiol would be effective as a potential future treatment modality for both hormone sensitive and hormone refractory prostate cancer.